A double-blind, placebo-controlled randomized trial of Vilazodone in the treatment of posttraumatic stress disorder and comorbid depression
Abstract
OBJECTIVE: To determine the efficacy, safety, and tolerability of vilazodone in the treatment of posttraumatic stress disorder (PTSD) with comorbid mild-to-moderate depression. METHODS: A 12-week randomized, double-blind, placebo-controlled trial was conducted in adult outpatients who met DSM-IV criteria for PTSD with comorbid depression between February 2013 and September 2015. Participants were randomly assigned to receive vilazodone 40 mg/d or placebo, and outcome measures were obtained at scheduled visits. Primary outcome measures included change in PTSD symptoms from baseline to end of study as indexed by the Clinician-Administered PTSD Scale (CAPS) and PTSD Symptom Scale-Self-Report (PSS-SR). Secondary outcome measures of anxiety, depression, and impairment were obtained, as well as biomarker assessment at baseline and end of study. RESULTS: A total of 59 patients were randomly assigned to receive vilazodone (n = 29) or placebo (n = 30). Of those who were randomized, there were 25 completers in the vilazodone group and 22 completers in the placebo group. No significant differences were observed between the groups on any of the primary or secondary outcome measures. Vilazodone was generally well tolerated with few differences in the rate of adverse events between groups. CONCLUSIONS: Treatment with vilazodone 40 mg/d did not improve symptoms of PTSD and comorbid depression. Further investigation of the biological mechanisms underlying PTSD may lead to identification of improved therapeutic targets. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01715519.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Symptoms of PTSD and comorbid depression have not been found to be improved by vilazodone.
“In contrast, symptoms of PTSD and comorbid depression have not been found to be improved by vilazodone (Ramaswamy et al., 2017).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Ramaswamy et al., 2017
Cited by
Sorted by citations
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236 · see citing works
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub4 · Cited by 98 · see citing works
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. C. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub3 · Cited by 73 · see citing works
Huang, Z.-D., Zhao, Y.-F., Li, S., Gu, H.-Y., Lin, L., Yang, Z.-Y., Niu, Y., Zhang, C., & Luo, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00559 · Cited by 47 · see citing works
Bajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43 · see citing works
Davis, L. L., & Hamner, M. B. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1356563 · Cited by 32 · see citing works
Sleep management in posttraumatic stress disorder: a systematic review and meta-analysis
Maher, A. R., Apaydin, E. A., Hilton, L. G., Chen, C., Troxel, W., Hall, O., Azhar, G. S., Larkin, J., Motala, A., & Hempel, S. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.08.016 · Cited by 23 · see citing works
Evaluation of vilazodone for the treatment of depressive and anxiety disorders
Stuivenga, M., Giltay, E. J., Cools, O., Roosens, L., Neels, H., & Sabbe, B. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1549542 · Cited by 24 · see citing works
“[25] included patients with a posttraumatic stress disorder (PTSD) in combination with a comorbid depression.”
BackgroundResultCosta, G. D. M., Ziegelmann, P. K., Zanatta, F. B., Martins, C. C., Costa, P. D. M., & Mello, C. F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110557 · Cited by 15 · see citing works
Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews
Lappas, A. S., Polyzopoulou, Z. A., Christodoulou, G. N., Bozikas, V., & Samara, M. T. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230801144328 · Cited by 12 · see citing works
Guidetti, C., Feeney, A., Hock, R. S., Iovieno, N., Ortiz, J. M. H., D, M. F. M., & Papakostas, G. I. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000554 · Cited by 13 · see citing works
“…., 2000; Davidson et al ., 2001, 2006; Marshall et al ., 2001, 2007; Tucker et al ., 2001, 2003; Martenyi et al ., 2002, 2007; Zohar et al ., 2002; Stein et al ., 2003; Davis et al ., 2004, 2020; Friedman et al ., 2007; Van Der Kolk et al ., 2007; Fani et al ., 2009, 2011; Ramaswamy et al ., 2017).”
Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder
Dunlop, B. W., Rakofsky, J. J., Newport, D. J., Mletzko, T., Barone, K., Nemeroff, C. B., & Harvey, P. D. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001363 · Cited by 10 · see citing works
Mechanism of action of sedatives, hypnotics, and antianxiety drugs
Nisar, M. A., & Saleem, M. Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99855-0.00007-5 · Cited by 7 · see citing works
Predictors of PTSD Treatment Retention and Response: A Systematic Review
Maglione, M., Chen, C., Franco, M., Gizaw, M., Shahidinia, N., Baxi, S. M., & Hempel, S. (2022) · RAND Corporation eBooks · doi:10.7249/rr4191 · Cited by 4 · see citing works
Zhao, Y., Huang, Z.-D., Gu, H.-Y., Guo, G., Yuan, R., & Zhang, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602447 · Cited by 2 · see citing works
“In comparison with other drugs, α2 receptor agonist (mirtazapine) contrast SSRIs (sertraline) from (Chung et al., 2004) change in total PTSD symptoms scale: (SMD −0.57, 95% CI [−0.97, 0.17], I2 NA), acceptability: (RR 1.12, 95% CI [0.41, 3.10], I2 NA), response: (RR 1.04, 95% CI [0.82, 1.32], I2 NA), frequencies of co…”
BackgroundInfluentialYan, J.-Z., Liu, J.-L., Li, X., Zhang, Z., Liu, R.-B., Zhang, C., & Gong, Q.-Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.805354 · Cited by 2 · see citing works
“, 2007), and unreported or different combat locations (Davidson et al., 1990; Stein et al., 2002; Bartzokis et al., 2005; Neylan et al., 2006; Raskind et al., 2007; Davis et al., 2008; Naylor et al., 2015; Petrakis et al., 2016; Villarreal et al., 2016; Ramaswamy et al., 2017; Surís et al., 2017; Raskind et al., 2018).”
BackgroundThe Role(s) of Psychopharmacology in the Treatment of PTSD
Baig, M. R., & Roache, J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00150-x
- Authors
- Ramaswamy, S., Driscoll, D., Reist, C., Smith, L. M., Albers, L. J., Rose, J., Nguyen, L., Monga, V., Doria, R., & Hollifield, M.
- Affiliations
- Creighton University (US)
- VA Nebraska Western Iowa Health Care System (US)
- University of California, Irvine (US)
- University of Nebraska Medical Center (US)
- Banner Thunderbird Medical Center (US)
- Corresponding author
- Ramaswamy, Sriram
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2017-08-24
- Volume
- 19
- Issue
- 04
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- OpenAlex
- W2747485283
- Cited by
- 17
- References
- 0
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 1
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- vilazodone, post-traumatic stress disorder, comorbid depression, selective serotonin reuptake inhibitors, antidepressant efficacy, safety and tolerability, PTSD symptom severity, biomarkers, outpatients
- MeSH terms
- Vilazodone Hydrochloride, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Psychiatric Status Rating Scales, Stress Disorders, Post-Traumatic, Comorbidity, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
